• Cyanidin Chloride: Assay Design Beyond ROS

  2026-08-19

  Cyanidin Chloride supports rigorous oxidative stress research when chemical identity, radical assays, and cell-based endpoints are interpreted together. This guide turns a psoriasis-model study into practical decisions for evaluating reactive oxygen species scavenging and cellular protection without overextending the evidence.

• Leptin (116-130): Metabolic–Inflammatory Assays

  2026-08-19

  Leptin (116-130), amide, mouse is more than a tool for obesity models: it can help researchers design controlled experiments linking energy homeostasis regulation with inflammatory phenotypes. This article interprets the peptide alongside SIRT6-AMPK-NLRP3 research while clearly separating established evidence from testable cross-domain hypotheses.

• Tamoxifen Workflows for CreER and Cancer Research

  2026-08-18

  Tamoxifen is more than an estrogen-pathway tool: it enables conditional genetics, cancer-cell assays, and emerging tumor-immune studies. This workflow-focused guide shows how to control solubility, timing, model context, and mechanistic readouts for more reproducible experiments.

• 3-Deazaadenosine hydrochloride in m6A Workflows

  2026-08-18

  Use 3-Deazaadenosine hydrochloride as a pathway-level probe to test how SAHH-dependent methyl metabolism influences IGF2BP1–TUBB4B signaling in hepatic stellate cells. The workflow pairs pharmacological perturbation with genetic controls, RNA stability measurements, and fibrosis-relevant phenotyping for more interpretable results.

• 3-Aminobenzamide: A Translational PARP Playbook

  2026-08-17

  A thought-leadership analysis of 3-Aminobenzamide (PARP-IN-1) as a practical tool for connecting PARP biology with oxidative injury, vascular dysfunction, diabetic nephropathy research, and carefully bounded antiviral investigations.

• Mifepristone (RU486): A Mechanism-First Assay Map

  2026-08-17

  Mifepristone (RU486) is more than a progesterone receptor antagonist: it is a tool for separating receptor dependence, tissue context, and phenotype in cancer and reproductive biology assays. This mechanism-first guide connects RU486 research with lessons from tissue-specific nuclear receptor pharmacology.

• Pam3CSK4: Designing Causal TLR1/2 Assays

  2026-08-16

  Pam3CSK4 is a precise TLR1/2 agonist for separating receptor-proximal immune activation from downstream inflammatory phenotypes. This guide presents a causal assay framework that connects macrophage, platelet, allergy, and neuro-immune readouts without conflating distinct biological pathways.

• Phenothiazines, ROS, and Macrophage Autophagy

  2026-08-15

  A 2025 Frontiers in Immunology study shows that phenothiazines can strengthen macrophage antibacterial activity through coordinated increases in reactive oxygen species, lysosomal function, and autophagy. Pharmacological inhibition of autophagy or ROS reduced this effect, while perphenazine improved inflammatory and tissue outcomes in a Salmonella Typhimurium infection model, supporting phenothiazines as lead compounds for host-directed antibacterial research.

• GS967: Cardiac Late Sodium Current Inhibitor

  2026-08-14

  GS967 enables targeted studies of pathological late sodium influx in ventricular myocytes, isolated hearts, aging models, and arrhythmia paradigms. Its concentration- and voltage-dependent activity supports experimental separation of late INa effects from broader conduction changes.

• GS967: Cardiac Late Sodium Current Inhibitor

  2026-08-14

  GS967 enables targeted interrogation of pathological late sodium influx in ventricular myocytes, aging models, isolated hearts, and ischemia-related arrhythmia assays. Its concentration- and voltage-dependent activity supports workflows that separate late sodium current effects from broader changes in cardiac conduction.

• Sabutoclax: From Viability Readouts to Cell Death

  2026-08-13

  Sabutoclax is a pan-Bcl-2 inhibitor whose effects can be interpreted more accurately by separating growth suppression from actual cell killing. This guide combines its multi-target pharmacology with a dissertation-based framework for selecting time-resolved, orthogonal cancer assays.

• CSBTA Pharmacokinetics in MASH: Study Insights

  2026-08-13

  The reference study integrates plasma pharmacokinetics, tissue distribution, cellular accumulation, transporter assays, and metabolic-enzyme analysis to explain how MASH changes exposure to Corydalis saxicola Bunting total alkaloids. Its findings show that disease state and repeated dosing can increase systemic and hepatic exposure, providing a mechanistic basis for disease-adjusted dosing strategies.

• RAB31 and ESCRT-Independent Exosome Biogenesis

  2026-08-12

  The reference study identifies RAB31 as a regulator of an ESCRT-independent exosome pathway in which EGFR-activated RAB31 engages flotillin microdomains to promote intraluminal vesicle formation. It also links RAB31 to TBC1D2B-mediated RAB7 inactivation, showing how one regulatory module can both generate vesicles and protect multivesicular endosomes from lysosomal degradation.

• GS967: Cardiac Late Sodium Current Workflows

  2026-08-12

  GS967 enables targeted suppression of pathological late sodium influx in cellular, tissue, and whole-heart models. Its concentration-dependent activity supports aging, ischemia, and torsades de pointes workflows while preserving a practical path for separating late-current effects from broader conduction changes.

• Valemetostat in Reliable Lymphoma Assays

  2026-08-11

  This scenario-based guide explains how Valemetostat (SKU BA4816) can be integrated into viability, proliferation, and cytotoxicity workflows without confusing biochemical potency with cellular response. It covers solvent compatibility, exposure design, EZH2-mutant comparisons, interpretation of lymphoma data, and practical product-selection criteria.

16280 records 1/1086 page Next 12345 下5页 Last page